(FTV) Fortive - NYSE
Sector: Technology | Industry: Scientific & Technical Instruments | Exchange: NYSE (USA) | Market Cap: 18.975m USD | Total Return: 15.7% in 12m
Avg Turnover: 196M
EPS Trend: -76.8%
Qual. Beats: 0
Rev. Trend: -64.5%
Qual. Beats: 0
Warnings
Fakeout
Tailwinds
No distinct edge detected
Fortive Corporation (FTV) is a diversified industrial technology company headquartered in Everett, Washington. The firm operates through two primary segments: Intelligent Operating Solutions and Advanced Healthcare Solutions. These divisions provide specialized instrumentation, sensing technology, and workflow software to industries ranging from manufacturing and utilities to clinical healthcare settings.
The company utilizes a multi-brand strategy, maintaining market positions through established names such as Fluke, Industrial Scientific, and ASP. This business model relies on high-margin recurring revenue streams generated through software-as-a-service (SaaS) and essential maintenance services. In the industrial machinery and components sector, firms like Fortive are increasingly shifting toward digital transformation to reduce cyclicality and improve long-term margins.
Investors may find ValueRays quantitative analysis useful for comparing Fortive’s valuation against its peer group. The company remains focused on the Fortive Business System, a continuous improvement methodology designed to optimize lean manufacturing and acquisition integration.
- Recurring software revenue growth accelerates margin expansion across Intelligent Operating Solutions
- Strategic portfolio reshaping via healthcare segment spinoff impacts long-term valuation
- Global industrial capital expenditure cycles dictate demand for Fluke instrumentation tools
- Consolidation of high-margin SaaS brands drives enterprise software segment profitability
- Regulatory compliance standards in healthcare sterilization drive recurring service demand stability
| Net Income: 543.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.18 > 1.0 |
| NWC/Revenue: -13.47% < 20% (prev -0.35%; Δ -13.12% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.08b > Net Income 543.7m |
| Net Debt (3.23b) to EBITDA (1.22b): 2.64 < 3 |
| Current Ratio: 0.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (312.8m) vs 12m ago -9.23% < -2% |
| Gross Margin: 61.83% > 18% (prev 59.98%; Δ 1.85% > 0.5%) |
| Asset Turnover: 32.99% > 50% (prev 36.07%; Δ -3.08% > 0%) |
| Interest Coverage Ratio: 6.73 > 6 (EBIT TTM 807.7m / Interest Expense TTM 120.1m) |
| A: -0.06 (Total Current Assets 1.55b - Total Current Liabilities 2.19b) / Total Assets 11.6b |
| B: 0.48 (Retained Earnings 5.55b / Total Assets 11.6b) |
| C: 0.06 (EBIT TTM 807.7m / Avg Total Assets 14.4b) |
| D: 1.11 (Book Value of Equity 6.08b / Total Liabilities 5.50b) |
| Altman-Z'' = 2.74 = A |
| DSRI: 0.91 (Receivables 647.0m/929.3m, Revenue 4.74b/6.18b) |
| GMI: 0.97 (GM 59.98% / 61.83%) |
| AQI: 1.03 (AQ_t 0.84 / AQ_t-1 0.82) |
| SGI: 0.77 (Revenue 4.74b / 6.18b) |
| TATA: -0.05 (NI 543.7m - CFO 1.08b) / TA 11.6b) |
| Beneish M = -3.28 (Cap -4..+1) = AA |
As of June 22, 2026, the stock is trading at USD 61.03 with a total of 5,619,600 shares traded. Over the past week, the price has changed by +1.99%, over one month by +3.41%, over three months by +10.18% and over the past year by +15.72%.
Current recommended Stop Loss: 59.00 (which is 3.3% or 1.3 ATR below the current price).
Fortive has received a consensus analysts rating of 3.24. Therefore, it is recommended to hold FTV.
- StrongBuy: 3
- Buy: 1
- Hold: 11
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 63.6 | 4.3% |
P/E Trailing = 36.6118
P/E Forward = 20.4918
P/S = 4.4814
P/B = 3.0786
P/EG = 1.2896
Revenue TTM = 4.74b USD
EBIT TTM = 807.7m USD
EBITDA TTM = 1.22b USD
Long Term Debt = 2.59b USD (from longTermDebt, last quarter)
Short Term Debt = 899.8m USD (from shortTermDebt, last quarter)
Debt = 3.59b USD (from shortLongTermDebtTotal, last quarter) + Leases 100.6m
Net Debt = 3.23b USD (calculated: Debt 3.59b - CCE 356.1m)
Enterprise Value = 22.2b USD (19.0b + Debt 3.59b - CCE 356.1m)
Interest Coverage Ratio = 6.73 (Ebit TTM 807.7m / Interest Expense TTM 120.1m)
EV/FCF = 22.86x (Enterprise Value 22.2b / FCF TTM 971.3m)
FCF Yield = 4.37% (FCF TTM 971.3m / Enterprise Value 22.2b)
FCF Margin = 20.50% (FCF TTM 971.3m / Revenue TTM 4.74b)
Net Margin = 11.48% (Net Income TTM 543.7m / Revenue TTM 4.74b)
Gross Margin = 61.83% ((Revenue TTM 4.74b - Cost of Revenue TTM 1.81b) / Revenue TTM)
Gross Margin QoQ = 63.17% (prev 63.15%)
Tobins Q-Ratio = 1.92 (Enterprise Value 22.2b / Total Assets 11.6b)
Interest Expense / Debt = 3.35% (Interest Expense 120.1m / Debt 3.59b)
Taxrate = 10.66% (73.0m / 684.5m)
NOPAT = 721.6m (EBIT 807.7m * (1 - 10.66%))
Current Ratio = 0.71 (Total Current Assets 1.55b / Total Current Liabilities 2.19b)
Debt / Equity = 0.59 (Debt 3.59b / totalStockholderEquity, last quarter 6.08b)
Debt / EBITDA = 2.64 (Net Debt 3.23b / EBITDA 1.22b)
Debt / FCF = 3.33 (Net Debt 3.23b / FCF TTM 971.3m)
Total Stockholder Equity = 7.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.79% (Net Income 543.7m / Total Assets 11.6b)
RoE = 7.39% (Net Income TTM 543.7m / Total Stockholder Equity 7.36b)
RoCE = 8.12% (EBIT 807.7m / Capital Employed (Equity 7.36b + L.T.Debt 2.59b))
RoIC = 7.17% (NOPAT 721.6m / Invested Capital 10.1b)
WACC = 8.37% (E(19.0b)/V(22.6b) * Re(9.39%) + D(3.59b)/V(22.6b) * Rd(3.35%) * (1-Tc(0.11)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.11 | Cagr: -5.41%
[DCF] Terminal Value 73.02% ; FCFF base≈1.14b ; Y1≈1.00b ; Y5≈811.3m
[DCF] Fair Price = 31.95 (EV 13.0b - Net Debt 3.23b = Equity 9.74b / Shares 304.9m; r=8.37% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -76.85 | EPS CAGR: -15.06% | SUE: 0.62 | # QB: 0
Revenue Correlation: -64.51 | Revenue CAGR: -6.00% | SUE: 0.08 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.71 | Chg30d=+0.21% | Revisions=+56% | Analysts=14
EPS next Quarter (2026-09-30): EPS=0.71 | Chg30d=+0.09% | Revisions=-43% | Analysts=15
EPS current Year (2026-12-31): EPS=3.00 | Chg30d=+0.31% | Revisions=+25% | GrowthEPS=+10.6% | GrowthRev=+4.3%
EPS next Year (2027-12-31): EPS=3.22 | Chg30d=+0.26% | Revisions=+40% | GrowthEPS=+7.5% | GrowthRev=+3.7%
[Analyst] Revisions Ratio: +56%